Trust staff to provide clinical guidance to tenants & across SBC network
Stevenage, UK, February 6 2017 – Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, and the East and North Hertfordshire NHS Trust are pleased to announce a clinical expertise partnership. Under this new relationship, physicians and other staff from the Trust will join SBC's Experts Panel and provide guidance on clinical matters to tenants. Other SBC activities, such as academic projects in the University laboratories and the DiscoverAssist drug discovery service, are also expected to benefit from this initiative.
The East and North Hertfordshire NHS Trust, which includes Hertford County Hospital, the Lister Hospital, Mount Vernon Cancer Centre and the New QEII Hospital, has major strengths in cancer, renal disease, cardiovascular disease, diabetes and robotic surgery. Associate Director of R&D, Dr Phillip Smith, has joined SBC's Experts Panel and will be invaluable in helping tenants carry out research in the NHS.
Martino Picardo, CEO of Stevenage Bioscience Catalyst, said, 'We welcome the East and North Hertfordshire NHS Trust to the SBC network and Experts Panel. The clinical guidance and access to NHS research capabilities it brings will be invaluable to our mission of creating impact through innovation.'
Phillip Smith, Associate Director of R&D at the Trust, added, 'Working with Stevenage Bioscience Catalyst is an exciting new initiative for the East and North Hertfordshire NHS Trust, and we are looking forward to helping it progress a range of projects and technologies. Relationships such as these are important in helping us deliver on our Research Strategy – 'Enhancing patient outcome and experience through research and innovation'.
For more information, please contact:
Stevenage Bioscience Catalyst
Martino Picardo, CEO
Emma Palmer Foster, Strategic Communications Consultant
East and North Hertfordshire NHS Trust
Phillip Smith, Associate Director Research and Development
Notes for Editors
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst (SBC) opened as the UK's first open innovation biomedical campus in 2012, and combines a unique blend of infrastructure and virtual networks to drive collaboration. Backed by a novel partnership between Government, GlaxoSmithKline and Wellcome, the remit was, and remains, to catalyse innovation for patient benefit in a phased development. SBC has a strong commitment to companies that focus on high quality science and share its vision, and its development of activity clusters and direct access to the expertise of a major pharmaceutical company are among its unique characteristics. There is start-up and grow-on space for companies, plus ac ommercially focused management team viewed as a leader in UK incubation. With Phase 1 at capacity, the next phase is in development for the continuation of the collaborative vision. Co-located with GlaxoSmithKline in Stevenage, Stevenage Bioscience Catalyst is located close to both London and Cambridge. For more information, please go to www.stevenagecatalyst.com. Follow us on twitter @SteBioCat
About Stevenage Bioscience Catalyst's stakeholders
Stevenage Bioscience Catalyst's stakeholders are GlaxoSmithKline (www.gsk.com), Wellcome (www.wellcome.ac.uk), the Department for Business, Energy and Industrial Strategy (www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy; formerly the Department for Business, Innovation and Skills), and Innovate UK (formerly the Technology Strategy Board; www.innovateuk.org).
About East and North Hertfordshire NHS Trust
At the East and North Hertfordshire NHS Trust we are proud of the wide range of general andspecialist services we provide to our patients. We have over 5,000 dedicated staff making sure our patients get the best care.
Ourf our hospitals are:
In terms of the numbers of patients we see at our hospitals, here are the latest figures for 2015/16 taken from our annual report:
The Trust recognises that developing a research-active culture can bring a host of benefits for patients,clinicians and the NHS, driving innovation, giving rise to better and more cost-effective treatments, and creating opportunities for staff development.
A Research Strategy for 2016 -19 has been produced which aims to enhance patient experience and outcomes by offering research opportunity and innovation for all patients and all staff. For further information on the Trust please see our website http://www.enherts-tr.nhs.uk/